Research Article

Attitude towards Antipsychotic Medications in Patients Diagnosed with Schizophrenia: A Cross-Sectional Study at Amanuel Mental Specialized Hospital, Addis Ababa, Ethiopia

Tilahun Kassew,1 Demeke Demilew,1 Addis Birhanu2, Mesele Wonde,1 Biks Liyew,3 and Shegaye Shumet1

1Department of Psychiatry, University of Gondar, Gondar, Ethiopia
2Amanuel Mental Specialized Hospital, Addis Ababa, Ethiopia
3Department of Emergency and Critical Care Nursing, University of Gondar, Gondar, Ethiopia

Correspondence should be addressed to Shegaye Shumet; shumetshegaye@yahoo.com

Received 29 January 2019; Revised 6 April 2019; Accepted 15 May 2019; Published 22 May 2019

Academic Editor: Hugo Schnack

Copyright © 2019 Tilahun Kassew et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Poor attitude towards antipsychotic drugs is high, and it is a factor for non-adherence to treatment. This increases the risk of relapse, associated healthcare utilization, and costs. This study aimed to assess attitude towards antipsychotic medication among patients with schizophrenia. Objectives. The aim of this institution based cross-sectional study was to assess attitude towards antipsychotic medications and associated factors among patients with schizophrenia who attend the outpatient clinics at Amanuel Mental Specialized Hospital, 2018. Methods. In a cross-sectional study, 393 schizophrenic patients from Amanuel Mental Specialized Hospital were recruited by a systematic random sampling technique. Drug Attitude Inventory (DAI-10) was used to assess attitude, experience, and belief about antipsychotics. Glasgow antipsychotic side effect scale modified version, positive and negative syndrome scale, and Birch wood’s insight scale for psychosis were the instruments used to assess the associated factors. Simple and multiple linear regression analysis models were fitted, and the adjusted unstandardized beta (\( \beta \)) coefficient at 95% confidence interval was used. Results. The mean score of attitude towards antipsychotic medications was 6.51 with standard deviation (SD) of 2.22. In multiple linear regression, positive symptoms (\( \beta = -0.07, 95\% CI: (-0.09, -0.05) \)), negative symptoms (\( \beta = -0.04, 95\% CI: (-0.06, -0.02) \)), shorter (\( \leq 5\) years) duration of illness (\( \beta = -0.39, 95\% CI: (-0.63, -0.15) \)), first generation antipsychotics (\( \beta = -0.35, 95\% CI: (-0.55, -0.14) \)), having sedation (\( \beta = -0.28, 95\% CI: (-0.52, -0.02) \)), and extra-pyramidal side effects (\( \beta = -0.34, 95\% CI: (-0.59, -0.09) \)) were factors negatively associated with attitude towards antipsychotic medication treatment. Insight to illness (\( \beta = 0.24, 95\% CI: (0.20, 0.27) \)) was a factor positively associated with attitude towards antipsychotic medications. Conclusion. The result suggests that the mean score of participants’ attitude towards antipsychotic medications was good. Prevention of side effects particularly due to first generation antipsychotics is necessary.

1. Introduction

Schizophrenia is a chronic psychotic disorder with impaired thinking, emotions, and behaviors that affect family relationships, social functioning, and employment. The lifetime prevalence of schizophrenia is 1.0% [1]. Antipsychotic medications are the first line choice of treatment options for patients with schizophrenia. These drugs enhance recovery by controlling symptoms, improving quality of life, regaining basic life functioning, and preventing relapse [2, 3].

Attitude towards antipsychotic medication is the subjective feelings, beliefs, experiences, and opinions of patients with schizophrenia towards the prescribed antipsychotic drugs [4, 5].

Drug compliance in patients with schizophrenia is predicted by the patients’ attitude towards medications [6, 7]. Negative attitude towards antipsychotic medication is common in clinical practice with the prevalence ranges from 7.5%-46.7% [8–11]. Up to 75% of those with a negative attitude have non-adherence to antipsychotic drugs,
which results in a relapse. The prevalence of relapse due to non-adherence varies from 50% to 92% globally [6, 12]. Patients with schizophrenia are most likely to die early from potentially treatable conditions as a result of non-adherence to prescribed medications [13–15]. Most cases of re-hospitalization of patients diagnosed with schizophrenia are due to non-adherence to medication, which results from a negative attitude towards medication [16–18].

There are several moderating factors for poor attitude towards medication. The moderating factors were younger age [5, 8], male in sex [5, 19], being employed [20–22], urban residence, and living alone, which have a negative relationship with attitude towards medication [22]. Poor attitude towards antipsychotic medication was more common among patients with schizophrenia with a shorter duration of illness (less than five years) [8, 21, 23, 24], later age at onset of illness [25], and having frequent psychiatric hospital admissions [26]. The other important clinical moderating factors for attitude towards medication were the levels of positive symptoms, negative symptoms, and general psychopathology [8, 21, 22, 25, 27, 28], which also have a negative relationship with attitude towards medication. Insight of illness has a positive association with attitude towards medication [5, 25, 29].

Patients who are taking first-generation antipsychotics (FGAs) and depot medications [25, 29] had a more negative attitude towards their treatment. The side-effect burden is often viewed as an important reason for a poor attitude towards antipsychotic medication [20, 30, 31]. Antipsychotic-induced side-effects like dyskinesia, parkinsonism, sexual dysfunction, and sedation were the factors associated with a negative attitude towards antipsychotic medications [9, 21, 28, 30–32]. The severity of side effects is another factor, which affects the attitude towards antipsychotic drugs with a negative relationship [5, 9]. Poor attitude towards antipsychotic medication is also affected by illicit drug use as a result of worsening psychotic symptoms, which leads to poor outcome of the illness [33, 34].

In our clinical observations, many schizophrenic patients discontinue their prescribed medications and re-hospitalized due to relapse of the illness, which result in a high cost for a health care system. Different studies [6, 12] have showed that more than half of patients with schizophrenia have non-adhere to antipsychotic drugs due to their negative attitude towards the medication. Even though attitude has an impact on antipsychotic medication compliance, there is no study showing attitude of patients diagnosed with schizophrenia towards antipsychotic medication in Ethiopia. So identifying attitude of patients diagnosed with schizophrenia towards antipsychotic medication is important for controlling psychotic symptoms, decreasing the burden of relapse, and regaining basic life functioning, which all contributes for improving patients’ quality of life.

2. Methods and Materials

2.1. Study Settings and Populations. Institution based cross-sectional study design was conducted among patients diagnosed with schizophrenia who had follow-up at Amanuel Mental Specialized Hospital (AMSH) in Addis Ababa, Ethiopia, between May and June 2018. Systematic random sampling technique was used to recruit 393 study subjects. The sampling fraction (k) was calculated from the average monthly patients with schizophrenia who had visited the hospital divided by sample size, which was 8. The first participant was chosen randomly by lottery method from numbers 1 to 8. Then, every 8th patient was interviewed.

2.2. Measurement. The patients’ attitude towards antipsychotic medications was assessed with the 10-items Drug Attitude Inventory (DAI-10) 10-Item. The items of the questionnaire are about the benefits and perceived effects of antipsychotic drugs. The patients’ response for the questions was true or false and rated as 0 if response for the asked question is incorrect and 1 if response for asked questions is correct. The total score ranges from 0 to 10. Individuals with the total score closer to 0 indicates very poor attitude and those with the total score closer to 10 indicates best possible attitude on DAI-10 [4].

Symptoms of psychosis were measured using Positive and Negative Syndrome Scale (PANSS), which has three subscales: positive symptoms, negative symptoms, and general psychopathology subscales [35]. Insight to illness was measured using Birchwood’s Insight Scale for psychosis (BIS). The instrument is used to assess the three areas of insight, insight into the need for treatment, awareness of illness, and the ability to relabeling experiences. BIS is an 8-item self-report scale, which is a 3-point scale with higher scores indicating better insight [36].

The prevalence, type, and severity of antipsychotic side effects were assessed using the 22-item, modified version of Glasgow Antipsychotic Side effect Scale (GASS). Side effects assessed by GASS were sedation/cognition, cardio-vascular side effects, extrapyramidal symptoms (EPS), anticholinergic side effects, gastrointestinal, genitourinary side effects, screening of diabetes mellitus, prolactin/endocrine side effects, and weight gain. The extent of side effects is rated from none (0) to everyday (3 points) for questions 1-20 and no (0) and yes (3 points) for questions 21-22. Patients with a total score of 0-12 indicate absent/mild side effects, 13-26 moderate side effects, and over 26 severe side effects [37].

Items on socio-demographic factors (age, sex, ethnicity, religion, marital status, educational status, and occupational status) were adopted from different articles.

2.3. Data Collection. Structured questionnaires including socio-demographic, illness related, medication related, substance related characteristics, and DAI-10 questionnaires were used to collect the data. Data were collected by four trained data collectors (four mental health professionals) using the Amharic version of the questionnaire for a month. The questionnaire was designed in English and was translated to Amharic, the official language of Ethiopia and back to English, forward and backward translation for its consistency. The training was on introduction to antipsychotic medications, research methods, interviewing skills, sampling and recruitment, and ethical aspects of research.
Table 1: Socio-demographic and substance related characteristics of patients with schizophrenia at AMSH, 2018 (n=393).

| Variables               | Frequency | Percent (%) |
|-------------------------|-----------|-------------|
| Sex                     |           |             |
| Male                    | 243       | 61.8        |
| Female                  | 150       | 38.20       |
| Marital status          |           |             |
| Unmarried               | 207       | 52.7        |
| Married                 | 122       | 31          |
| Divorced                | 38        | 9.7         |
| Others                  | 26        | 6.6         |
| Educational status      |           |             |
| Unable to read and write| 49        | 12.5        |
| Primary school          | 123       | 31.3        |
| Secondary school        | 126       | 32.1        |
| Diploma and above       | 95        | 24.2        |
| Job status              |           |             |
| Unemployed              | 285       | 72.5        |
| Employed                | 108       | 27.5        |
| Living arrangement      |           |             |
| Living alone            | 60        | 15.3        |
| Living with family/supporters | 330   | 84.7        |
| Residence               |           |             |
| Urban                   | 262       | 66.7        |
| Rural                   | 131       | 33.3        |
| Current substance use   |           |             |
| Yes                     | 120       | 30.5        |
| No                      | 273       | 69.5        |
| Type of substances      |           |             |
| Khat chewing            | 87        | 22.1        |
| Alcohol use             | 56        | 14.2        |
| Cigarette smoking       | 76        | 19.3        |
| Other substances        | 10        | 2.5         |
| Age                     |           |             |
| Mean= 36.4             | SD= 9.93  |             |

Others= separated + widowed, other substances= Marijuana, shisha, drugs.

2.4. Data Processing and Analysis. Data were checked for completeness and consistency. A coded variable was entered into EpiData version 3.1, then exported to and analyzed using SPSS version 20. Descriptive statistics (frequency, percent, mean, and standard deviation) were used to summarize the distribution of variables. Assumption test was checked before conducting the regression analysis. Simple linear regression analysis was performed to test an association between attitude towards antipsychotic medication and each independent variable. Variables with p-value ≤0.05 during simple linear regression analysis were selected for further analysis in multiple linear regression analysis and model fitness test (adjusted R²) was also checked. Factors associated with the attitude towards antipsychotic medication were expressed as adjusted unstandardized β coefficient by employing 95% confidence level. A p-value of < 0.05 was considered as statistically significant.

2.5. Ethical Consideration. Ethical approval was obtained from the joint Ethical Review Committee (ERC) of University of Gondar and Amanuel Mental Specialized Hospital. An informed written consent was obtained from the participants. For the individuals younger than 18 years, written informed assent was obtained from their guardians after explaining the purpose of the study. Confidentiality was maintained by omitting their personal identification.

3. Results

A total of 393 participants took part in the study, with the response rate of 98.4%. The mean age of the participants was 36.40 (SD, 9.93) ranging from 15 to 65 years. Nearly, half of the study participants, i.e., N=207 (52.7%), were unmarried and 243 (61.80%) were males. Nearly one-third of the study participants, i.e., N=126 (32.1%), attended secondary school education. The majority of participants, N=262 (66.7%), were from the urban area and 285 (72.5%) of the participants were unemployed. Most of the study participants, N=330 (84.7%), were living with their family/supporters and 120 (30.7%) of the participants were currently using substances for non-medical purpose (Table 1).

The mean age of onset for schizophrenia was found to be 26.77 (SD±7.23). In total, 146 (37.15%) participants were included; duration of illness was 6 to 10 years. Regarding their psychiatric hospital admission history, approximately, half of the study participants did not have previous hospital admission. Only 28 (7.1%) patients had co-morbid medical/mental illness including diabetes mellitus, hypertension, HIV/AIDS, depression, and substance use disorder. The mean total score for degree of psychopathology and insight were 73.65 [SD ± 30.48], 8.9 [SD ± 3.8]), respectively (see Table 2).

Regarding the class of antipsychotics, 224 (57%) of the patients were on first generation antipsychotics (FGAs)
Table 2: Clinical characteristics of patients with schizophrenia on follow-up at AMSH, 2018 (n=393).

| Variables                                | Categories            | Frequency | Percent (%) |
|------------------------------------------|-----------------------|-----------|-------------|
| Duration of illness                      | 1-5 years             | 109       | 27.7        |
|                                           | 6-10 years            | 146       | 37.1        |
|                                           | >10 years             | 138       | 35.2        |
| Psychiatric hospital admission           | No admission          | 196       | 49.9        |
|                                           | 1-5 times             | 162       | 41.2        |
|                                           | ≥6 times              | 35        | 8.9         |
| Co-morbid chronic medical/ mental disorder | Yes*                  | 28        | 7.1         |
|                                           | No                    | 365       | 92.9        |

Ranges | Mean | SD |
---|------|----|
Age of onset of the illness in years | 12-52 | 26.77 | 7.23 |
PANSS total score | 30-142 | 73.65 | 30.48 |
PANSS positive subscale score | 7-44 | 17.51 | 9.38 |
PANSS negative subscale score | 7-45 | 19.23 | 8.89 |
PANSS general psychopathology Score | 16-87 | 37.18 | 15.80 |
Birchwood's insight scale score | 0-16 | 8.9 | 3.80 |
Relabeling experiences | 0-4 | 2.09 | 1.17 |
Awareness of illness | 0-4 | 1.74 | 1.14 |
Awareness of need of Rx | 0-8 | 5.08 | 2.16 |

* Diabetes, hypertension, HIV/AIDS, depression, substance related disorders; Rx = treatment.

Table 3: Drug therapy related characteristics among patients with schizophrenia on follow-up at AMSH, 2018 (n=393).

| Variables                                | Categories            | Frequency | Percent (%) |
|------------------------------------------|-----------------------|-----------|-------------|
| Class of antipsychotics                  | FGAs                  | 224       | 57          |
|                                           | SGAs                  | 123       | 31.3        |
|                                           | FGAs+ SGAs            | 46        | 11.7        |
| No of antipsychotic drug                 | Single                | 311       | 79.1        |
|                                           | Two or more           | 82        | 20.9        |
| Route of use                             | Per mouth             | 274       | 69.7        |
|                                           | Parenteral            | 42        | 10.68       |
|                                           | Combined route        | 77        | 19.59       |
| Frequency                                | Once                  | 274       | 69.7        |
|                                           | Twice a day           | 119       | 30.3        |
| CPZeq dose                               | <300mg                | 232       | 59.0        |
|                                           | 300-600mg             | 61        | 15.5        |
|                                           | 600-1000mg            | 45        | 11.5        |
|                                           | >1000mg               | 55        | 14.0        |
| Any adjuvant drug                        | No                    | 315       | 80.2        |
|                                           | Yes*                  | 78        | 19.8        |

Note: * * * Amitriptyline, Na+ valproate, fluoxetine, bezhexol, benzodiazepines Combined route= per mouth and parenteral, FGAs= First Generation Antipsychotics; SGAs= Second-Generation Antipsychotics.

medications. Over a fifth of the participants were on two or more antipsychotics medications and nearly one-third were on depot medications. The majority of them were on <300 mg CPZeq dose category (see Table 3).

The severity of side effects was rated as mild, moderate, and severe according to Glasgow Antipsychotic Side-effect Scale. About 193 (49.1%) of the participants experienced absent/mild side effects, 123 (31.3%) had moderate side effect, and 77 (19.4%) of them had a severe side effect. The majority of the patients (88.8%) were experiencing at least one side effect due to their medications based on Glasgow antipsychotic side effects rating scale (GASS). Sedation was the most frequent side effect (65.6%) (Figure 1).

3.1. Attitude towards Antipsychotic Medications among Patients with Schizophrenia. The mean score of attitude
towards antipsychotic medication was 6.51 (95% CI 6.28, 6.74) with the standard deviation of 2.22.

3.2. Factors Associated with Attitude towards Antipsychotic Medications. Simple linear regression analysis indicated that residency, duration of illness, onset of age of illness, PANSS positive subscale, PANSS negative subscale, general psychopathology, class of antipsychotic drugs, number of antipsychotic drugs and route, presence of side effect (sedation, extrapyramidal symptoms, sexual dysfunction), and current substance use were factors negatively associated with attitude towards antipsychotic medications with p-value ≤0.05. Insight to illness was a factor positively associated with attitude towards antipsychotic medications. Results of multiple linear regressions showed that higher PANSS positive and negative scores, shorter duration (≤5 years) of illness, having poor insight to illness, FGAs, having sedation, and extrapyramidal symptoms were factors associated with negative attitude towards antipsychotic medications.

Attitude towards antipsychotic medications is negatively associated with positive and negative symptoms, shorter duration of the illness, treated with FGAs, presence of sedation, and extrapyramidal symptoms, whereas attitude towards antipsychotic medications is positively associated with insight to illness (Table 4).

4. Discussion

Antipsychotic medications are the treatment options for patients diagnosed with schizophrenia. They enhance control for symptoms, prevent relapse, help patients regain basic life functioning, and improve quality of life [2, 3]. For these positive outcomes of antipsychotics, patients' adherence to their medication is necessary [38]. Patients' attitude towards their medication may significantly affect the subjective response to anti psychotics. Studies showed [6,12] that nearly three-fourth of patients with negative attitude towards their medication have non-adherence to antipsychotic drugs. Our findings indicate that the majority of the respondents had a positive attitude towards antipsychotic medication with mean score of 6.51 (95% CI = 6.27, 6.74). The proportion of those who had a positive attitude towards antipsychotic medication was 51.9%. If the DAI represents an indirect indication for compliance, then the level of non-compliance in our sample was 48.1%. It indicates that nearly half of patients with schizophrenia had non-compliance to their medication. This finding is supported by Nigeria’s study with mean score of 6.71 [20]. In the current study, we had a mean higher drug attitude score in patients, as compared to a study conducted in Bulgaria, South Korea, Spain, and USA [24, 27, 39, 40]. The possible reason for the variation might be attributed to the approach to the summation of the items, sample size difference, the study design, socio-cultural differences, and difference between participants. In this study, the approach of scoring of the items was by giving 0 and 1 values, which result in the sum total ranges of 0–10, whereas in Bulgaria, South Korea, and USA -1 and/1 values were used for the alternatives and the sum total ranges of -10 to10s. So this finding is supposed to increase the mean score of attitude towards antipsychotic medications. The sample size was higher in this study compared to that of Bulgaria, South Korea, and Spain. The USA study was a large multi-center prospective study whereas in our study, we used a cross-sectional study design, which may have resulted in the mean score difference. In the Spanish study, the participants were hospital discharged patients. But in this study, the participants were patients with schizophrenia on a follow-up, which may have increased the mean score.

Regarding predictor variables, shorter (≤5 years) duration of illness was significantly associated with a negative attitude towards antipsychotic medication. The possible reason might be when duration of illness is short, patients might have poor insight about their illness and in need for treatment, which results in negative attitude towards their medication. This finding was consistent with previous studies [8, 21, 23–25]. The degree of psychopathology was negatively associated with attitude towards antipsychotic medications. Patients with severe positive symptoms and negative symptoms had
Table 4: Factors associated with attitude towards antipsychotic medications during multiple linear regression analysis (n=393).

| Variables                      | Crude unstandardized $\beta$ coefficient (95% CI) | Adjusted unstandardized $\beta$ coefficient (95% CI) |
|--------------------------------|--------------------------------------------------|-----------------------------------------------------|
| Residence                      |                                                  |                                                     |
| Rural                          | 0                                                | 0                                                   |
| Urban                          | -0.59 (-1.06, -0.12)                            | -0.10 (-0.29, 0.11)                                |
| Age of onset of illness        | 0.03 (0.002, 0.060)                              | 0.02 (-0.20, 0.24)                                 |
| duration of illness            |                                                  |                                                     |
| >10 years                      | 0                                                | 0                                                   |
| 5-10 years                     | 0.36 (-0.10, 0.82)                              | -0.08 (-0.31, 0.15)                                |
| ≤5 years                       | -2.49 (-2.92, -2.05)                            | -0.39 (-0.63, -0.15)*                               |
| PANSS positive score           | -0.2 (-0.209, -0.181)                           | -0.07 (-0.09, -0.05)*                              |
| PANSS negative score           | -0.19 (-0.21, -0.17)                            | -0.04 (-0.06, -0.02)*                              |
| PANSS general psychopathology score | -0.09 (-0.10, -0.08) | -0.004 (-0.01, 0.004) |
| BIS total score                | 0.49 (0.46, 0.52)                               | 0.24 (0.20, 0.27)*                                 |
| Class of drugs                 |                                                  |                                                     |
| SGAs                           | 0                                                | 0                                                   |
| FGAs+ SGAs                     | -0.58 (-1.19, 0.03)                             | -0.17 (-0.47, 0.13)                                |
| FGAs                           | -1.89 (-2.30, -1.48)                            | -0.35 (-0.55, -0.14)**                              |
| No of Antipsychotics           |                                                  |                                                     |
| Single                         | 0                                                | 0                                                   |
| ≥2                             | -1.64 (-2.16, -1.11)                            | -0.15 (-0.42, 0.12)                                |
| Route of use                   |                                                  |                                                     |
| Oral                           | 0                                                | 0                                                   |
| Parenteral                     | -1.36 (-1.83, -0.89)                            | 0.02 (-0.21, 0.25)                                 |
| Sedation side effects          |                                                  |                                                     |
| No                             | 0                                                | 0                                                   |
| Yes                            | -2.59 (-2.99, -2.20)                            | -0.28 (-0.52, -0.02)*                               |
| EPS symptoms                   |                                                  |                                                     |
| No                             | 0                                                | 0                                                   |
| Yes                            | -2.59 (-2.96, -2.23)                            | -0.34 (-0.59, -0.01)**                              |
| Sexual dysfunction             |                                                  |                                                     |
| No                             | 0                                                | 0                                                   |
| Yes                            | -0.75 (-1.19, -0.31)                            | 0.01 (-0.19, 0.20)                                 |
| Current substance use          |                                                  |                                                     |
| No                             | 0                                                | 0                                                   |
| Yes                            | -1.54 (-2.00, -1.08)                            | 0.02 (-0.20, 0.24)                                 |

Note: * p<0.05, ** p<0.01, *** p<0.001
Adjusted R$^2$ = 79.9%, F-test p-value<0.001.

an association with a poor attitude towards antipsychotic drugs. The possible reason might be due to the patients’ delusions, hallucinations, suspiciousness, hostility, and withdrawal behaviors, which may increase the likelihood of a poor attitude toward medication [25]. This result is in agreement with other studies [20, 21, 25, 27].

Insight to the illness had a positive association with the attitude towards antipsychotic medications treatment. If patients believe that they have a mental illness, aware of the benefit of treatment and of the social consequences of the disorder, they would have better subjective feelings and attitude towards the treatment. This finding was consistent with other studies [5, 20, 25, 28, 29, 32], which showed that negative subjective attitude towards drugs was associated with less insight.

In our study, patients treated with FGAs have a lower score of attitude towards antipsychotic medications as compared to patients on SGAs antipsychotic treatment. In fact, this might be due to the perception that these medications are less effective against negative symptoms and more noxious [41], which may result in a poor attitude towards their medications. This finding was in line with other studies [25, 26,
42, 43]. Sedation side effect was significantly associated with poor attitude to antipsychotic medications. Sedation may contribute to irregular drug indigestion, poor control, and increase in psychopathy, which may lead to a decrease in subjective awareness of well-being and patients’ subjective need to take medications [44]. This finding was similar to other studies [9, 20, 32, 44, 45]. In addition, this study showed that having EPS symptoms was significantly associated with a poor attitude towards antipsychotic drugs among patients with schizophrenia. The possible reason might be that many patients experience antipsychotic drugs as unpleasant and something bad that they would prefer to avoid it [46]. This finding was supported by other studies [9, 20, 31].

There were several limitations. The participants were stable patients attending the clinic regularly, who were motivated to participate in the study. Patients with a negative attitude to drugs that usually stop attended clinic early might be underrepresented. The other limitation is the cross-sectional nature of the study. Since we were using cross-sectional study design, it is difficult to assess attitude towards medication in the acute phase of the illness and to evaluate if there are changes in attitude towards medication in different phases of illness.

5. Conclusion

Patients with schizophrenia have a good mean score of attitude towards antipsychotic medications. The presence of symptoms (positive and negative), having poor insight into the illness, shorter duration of illness, treated with FGAs, and presence of side-effects like sedation and EPS were factors significantly associated with a negative attitude towards antipsychotic medications. The program designers and the clinicians should incorporate these factors to improve the patient’s attitude towards medications. Prevention of side effects particularly due to first generation antipsychotics is necessary.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Ethical Approval

The study proposal was initially approved by the ethical review board of the University of Gondar and Amanuel Mental Specialized Hospital.

Consent

Informed consent was obtained from participants and confidentiality was maintained by omitting their personal identification.

Conflicts of Interest

The authors declare that they have no competing interest.

Authors’ Contributions

Tilahun Kassew developed the proposal, supervised the data collection, analyzed the data, and wrote the draft manuscript. Demeke Demilew, Addis Birhanu revised the proposal and checked the data analysis. Mesele Wonde, Bisik Liyew revised the proposal and assisted in the data analysis. Shegaye Shumet revised the proposal, checked the data analysis, and revised and approved the manuscript.

Acknowledgments

The authors acknowledge university of Gondar and Amanuel Mental Specialized Hospital for funding the study. We extend our gratitude to data collectors, supervisors, and study participants for their time and effort. University of Gondar and Amanuel mental specialized hospital funded for the study.

References

[1] R. Tandon, W. Gaebel, D. M. Barch et al., “Definition and description of schizophrenia in the DSM-5,” Schizophrenia Research, vol. 150, no. 1, pp. 3–10, 2013.
[2] J. DiPiro, L. Robert, C. Gary, G. Barbara, and L. Posy, Pharmacotherapy, A Pathophysiologic Approach, McGraw - Hill, New York, NY, USA, 9th edition, 2014.
[3] D. Kasper, A. Fauci, S. Hauser, D. Longo, J. Jameson, and J. Loscalzo, Harrison’s Principles of Internal Medicine, vol. 19e, 2015.
[4] R. E. Nielsen, E. Lindström, J. Nielsen, and S. Levander, “DAI-10 is as good as DAI-30 in schizophrenia,” European Neuropsychopharmacology, vol. 22, no. 10, pp. 747–750, 2012.
[5] M. S. Kartik, N. Warikoo, S. Chakrabarti, S. Grover, and P. Kulhara, “Attitudes towards antipsychotics among patients with schizophrenia on first- or second-generation medications,” Indian Journal of Psychological Medicine, vol. 36, no. 3, pp. 288–293, 2014.
[6] J. M. Kirigia and L. M. Sambo, “Cost of mental and behavioural disorders in Kenya,” Annals of General Psychiatry, vol. 2, no. 1, p. 7, 2003.
[7] S. C. Burton, “Strategies for improving adherence to second-generation antipsychotics in patients with schizophrenia by increasing ease of use,” Journal of Psychiatric Practice, vol. II, no. 6, pp. 369–378, 2005.
[8] N. Kuroda, S. Sun, C.-K. Lin et al., “Attitudes toward taking medication among outpatients with schizophrenia: Cross-national comparison between Tokyo and Beijing,” Environmental Health and Preventive Medicine, vol. 13, no. 5, pp. 288–295, 2008.
[9] E. O. Katay, Impact of Side Effects of Antipsychotics on Attitude and Adherence to Treatment among Adult Psychiatric Outpatients at Mathari Hospital in Kenya, School of Pharmacy, University of Nairobi, 2014.
[10] M. Sajatovic, F. DiBiasi, and S. N. Legacy, “Attitudes toward antipsychotic treatment among patients with bipolar disorders and their clinicians: a systematic review,” Neuropsychiatric Disease and Treatment, vol. 13, pp. 2285–2296, 2017.
[11] J. H. Effiong and K. A. Umoh, “Medication non adherence in schizophrenia: prevalence and correlates among outpatients in a tertiary health care facility in Uyo, South-South Nigeria,” Clinical Medicine and Diagnostics, vol. 5, no. 6, pp. 107–113, 2015.
A. O. Adewuya, B. A. Ola, S. K. Mosaku, F. O. Fatoye, J. C. Day, R. P. Bentall, C. Roberts et al., “Attitudes toward antipsychotic medication and clinical outcomes in chronic schizophrenia,” Schizophrenia Bulletin, vol. 35, no. 2, pp. 336–346, 2009.

A. O. Adewuya, O. A. Owuore, A. R. Erinfolami et al., “Prevalence and correlates of poor medication adherence amongst psychiatric outpatients in southwestern Nigeria,” General Hospital Psychiatry, vol. 31, no. 2, pp. 167–174, 2009.

P. N. Mahadun and M. Marshall, “Insight and treatment attitude in schizophrenia: Comparison of patients on depot and atypical antipsychotics,” Psychiatric Bulletin, vol. 32, no. 2, pp. 53–56, 2008.

M. Lambert, P. Conus, P. Eide et al., “Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence,” European Psychiatry, vol. 19, no. 7, pp. 415–422, 2004.

M. A. Rettenbacher, A. Hofer, U. Eder et al., “Compliance in schizophrenia: psychopathology, side effects, and patients’ attitudes toward the illness and medication,” Journal of Clinical Psychiatry, vol. 65, no. 9, pp. 1211–1218, 2004.

O. Freudenreich, C. Cather, A. E. Eivins, D. C. Henderson, and D. C. Goff, “Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight,” Journal of Clinical Psychiatry, vol. 65, no. 10, pp. 1372–1376, 2004.

H. C. Margoless, L. Malchy, J. C. Negrete, R. Tempier, and K. Gill, “Drug and alcohol use among patients with schizophrenia and related psychosis: levels and consequences,” Schizophrenia Research, vol. 67, no. 2-3, pp. 157–166, 2004.

P. A. Ringen, I. Melle, A. B. Birkenaes et al., “Illicit drug use in patients with psychotic disorders compared with that in the general population: a cross-sectional study,” Acta Psychiatrica Scandinavica, vol. 117, no. 2, pp. 133–138, 2008.

S. R. Kay, A. Fiszbein, and L. A. Opler, “The positive and negative syndrome scale (PANSS) for schizophrenia,” Schizophrenia Bulletin, vol. 13, no. 2, pp. 261–276, 1987.

M. Birchwood, J. Smith, V. Drury, J. Healy, F. Macmillan, and M. Slade, “A self-report Insight Scale for psychosis: reliability, validity and sensitivity to change,” Acta Psychiatrica Scandinavica, vol. 89, no. 1, pp. 62–67, 1994.

L. Waddell and M. Taylor, “A new self-rating scale for detecting atypical or second-generation antipsychotic side effects,” Journal of Psychopharmacology, vol. 22, no. 3, pp. 238–243, 2008.

S. Loga-Zec and S. Loga, “Antipsychotics and the quality of life of schizophrenic patients,” Psychiatria Danubina, vol. 22, no. 4, pp. 495–497, 2010.

E. Medina, J. Salvà, R. Ampudia, J. Maurino, and J. Larumbe, “Short-term clinical stability and lack of insight are associated with a negative attitude towards antipsychotic treatment at discharge in patients with schizophrenia and bipolar disorder,” Patient Preference and Adherence, vol. 6, pp. 623–629, 2012.

J. Yang, Y.-H. Ko, J.-W. Paik et al., “Symptom severity and attitudes toward medication: Impacts on adherence in outpatients with schizophrenia,” Schizophrenia Research, vol. 134, no. 2-3, pp. 226–231, 2012.

D. Naber, A. Karow, and M. Lambert, “Subjective well-being under neuroleptic treatment and its relevance for compliance,” Acta Psychiatrica Scandinavica, Supplement, vol. 111, no. 427, pp. 29–34, 2005.

A. Karow, D. Schnedler, and D. Naber, “What would the patient choose? Subjective comparison of atypical and typical neuroleptics,” Pharmacopsychiatry, vol. 39, no. 2, pp. 47–51, 2006.
[43] L. Voruganti, L. Cortese, L. Owyeumi et al., “Switching from conventional to novel antipsychotic drugs: Results of a prospective naturalistic study,” Schizophrenia Research, vol. 57, no. 2-3, pp. 201–208, 2002.

[44] A. Hofer, G. Kemmler, U. Eder, M. Honeder, M. Hummer, and W. W. Fleischhacker, “Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia,” Journal of Clinical Psychiatry, vol. 63, no. 1, pp. 49–53, 2002.

[45] R. Baby, S. Gupta, and R. Sagar, “Attitudes and subjective reasons of medication compliance and noncompliance among outpatients with schizophrenia,” The Internet Journal of Epidemiology, vol. 7, no. 1, 2008.

[46] R. J. Wyat, “Neuroleptics and the natural course of schizophrenia,” Schizophrenia Bulletin, vol. 17, no. 2, pp. 325–351, 1991.